Advertisement

Topics

Catabasis Pharmaceuticals to Present at the 2017 Muscular Dystrophy Association Scientific Conference

08:00 EDT 13 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from Part B of the MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchen...

Other Sources for this Article

Corporate and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com

NEXT ARTICLE

More From BioPortfolio on "Catabasis Pharmaceuticals to Present at the 2017 Muscular Dystrophy Association Scientific Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...